Skip to main content
Clinical Trials/NCT06705270
NCT06705270
Not Yet Recruiting
N/A

Randomized Controlled Trial Comparing the Impact of Patient Education Strategies on the Antidepressant Response to Propofol Sedation

Stanford University0 sites20 target enrollmentSeptember 1, 2026

Overview

Phase
N/A
Intervention
Response-focused education
Conditions
Major Depressive Disorder (MDD)
Sponsor
Stanford University
Enrollment
20
Primary Endpoint
Depression severity
Status
Not Yet Recruiting
Last Updated
8 days ago

Overview

Brief Summary

The goal of this clinical trial is to understand how patient education surrounding a one-time, consciousness-altering medical intervention impacts the antidepressant response to the intervention in adults with major depressive disorder. In this study, the consciousness-altering medical intervention is a single infusion of propofol, an intravenous anesthetic which might have antidepressant properties.

The main question this study aims to answer is: Does the focus of patient education influence the antidepressant response to a single intravenous infusion of propofol?

Researchers will compare response-focused vs. diagnosis-focused education.

Qualifying participants will:

  • Undergo a single intravenous infusion of propofol which will induce a temporary state of sedation
  • Wear an EEG cap that records brain activity during sedation
  • Be randomized to receive either response-focused or diagnosis-focused education about their brain signals after they recover from sedation
  • Be asked to fill out surveys about their mood and other measures of well-being before and after treatment
Registry
clinicaltrials.gov
Start Date
September 1, 2026
End Date
October 1, 2028
Last Updated
8 days ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Theresa Lii

Principal Investigator

Stanford University

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of major depressive disorder of at least moderate severity
  • Able to read, understand, and provide written informed consent

Exclusion Criteria

  • Pregnant or breastfeeding
  • Certain substance use disorders
  • Daily use of opioids and/or benzodiazepines
  • History of psychosis, schizophrenia, or schizoaffective disorder
  • Body mass index greater than 35 kg/m2
  • Obstructive sleep apnea that is moderate and untreated, or severe
  • Any gastrointestinal condition placing the patient at significant risk of aspiration

Arms & Interventions

Response-focused education

Patient education that is focused on treatment response

Intervention: Response-focused education

Diagnosis-focused education

Patient education that is focused on the diagnosis of major depressive disorder

Intervention: Diagnosis-focused education

Outcomes

Primary Outcomes

Depression severity

Time Frame: From enrollment to 28 days after treatment

The 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR-16) assesses the severity of depressive symptoms experienced by an individual. Items are self-rated on a 4-point scale tailored to each depression symptom. Higher total scores indicate greater depression severity.

Similar Trials